Opdivo 240 mg/24 mL injection for intravenous use Images
Generic Name: nivolumab
This medication has been identified as Opdivo 240 mg/24 mL injection for intravenous use. It is supplied by Bristol-Myers Squibb Company.
Opdivo is used in the treatment of Esophageal Carcinoma; Head and Neck Cancer; Colorectal Cancer; Hepatocellular Carcinoma; Hodgkin's Lymphoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Opdivo 240 mg/24 mL injection for intravenous use is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Opdivo
- Generic Name
- nivolumab
- Strength
- 240 mg/24 mL injection for intravenous use
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-3734
More about Opdivo (nivolumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (80)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.